Prostate Adenocarcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 46 expanded access programs, clinical trials, and compassionate use pathways listed for Prostate Adenocarcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with prostate adenocarcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 15 programs are currently active or recruiting, with the remaining 31 in other lifecycle stages. Sponsors actively running programs in this area include NRG Oncology, Jonsson Comprehensive Cancer Center, M.D. Anderson Cancer Center, Mayo Clinic, National Cancer Institute (NCI), and others.
By recruiting status
Snapshot of where every Prostate Adenocarcinoma program currently sits in its lifecycle.
- Active / Recruiting15
- Inactive31
Top sponsors
Organisations running the most Prostate Adenocarcinoma programs in the directory.
- NRG Oncology7 programs
- Jonsson Comprehensive Cancer Center3 programs
- M.D. Anderson Cancer Center3 programs
- Mayo Clinic3 programs
- National Cancer Institute (NCI)3 programs
- City of Hope Medical Center2 programs
- University of Washington2 programs
- David Oh1 program
- ECOG-ACRIN Cancer Research Group1 program
- Emory University1 program
Prostate Adenocarcinoma programs (46)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- The LUNAR Study: 177-Lutetium-PSMA Before Targeted Radiation for Treating Recurrent Prostate Cancer — Jonsson Comprehensive Cancer Center
- Study on Lower Dose Radiation Therapy for Prostate Cancer — Memorial Sloan Kettering Cancer Center
- Study on Shortened Radiation Therapy for Recurrent or Limited Spread Prostate Cancer — Mayo Clinic
- Study on Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer — Wake Forest University Health Sciences
- Study on Abiraterone Acetate, Prednisone, and Apalutamide for Treating Patients with Untreated Metastatic Prostate Cancer — M.D. Anderson Cancer Center
- Study on Androgen Deprivation Therapy (Relugolix) to Improve Imaging in High Risk Prostate Cancer Patients — Mayo Clinic
- Study on Apalutamide for Prostate Cancer Patients Before Surgery — M.D. Anderson Cancer Center
- Study on the Use of rhPSMA-7.3 (18F) PET/CT for Men with Prostate Cancer Under Active Surveillance — Icahn School of Medicine at Mount Sinai
- Study on Androgen Ablation with or without Abiraterone Acetate and Prednisone for Recurrent Prostate Cancer — M.D. Anderson Cancer Center
- Study on Lu-177-PSMA-617 Treatment Before Surgery for High-Risk Localized Prostate Cancer — Hackensack Meridian Health
- Study on Nivolumab, Docetaxel, and Hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer — Xiao X. Wei, MD
- Study on Radium Ra 223, Hormone Therapy, and Targeted Radiation for Treating Metastatic Prostate Cancer — City of Hope Medical Center
- Study on Relugolix and Enzalutamide with Radiation Therapy for Treating Very High Risk Prostate Cancer (OPTIMAL Trial) — Northwestern University
- Study on Hormone and Radiation Therapy for Prostate Cancer — University of California, San Diego
- Study on Cabozantinib and Atezolizumab Compared to Second Hormonal Therapy in Men with Advanced Prostate Cancer — Exelixis
- Study on Enzalutamide and Relacorilant for High-Risk Localized Prostate Cancer — University of Chicago
- Study on Aspirin and Rintatolimod With or Without Interferon-alpha 2b for Prostate Cancer Treatment Before Surgery — Roswell Park Cancer Institute
- Study on Bipolar Androgen Therapy and Radium-223 for Advanced Prostate Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation — SWOG Cancer Research Network
- Study on Green Tea Extracts for Men Under Active Surveillance for Prostate Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study on Combining EPI-7386 with Enzalutamide and Hormone Therapy for Metastatic Hormone-Sensitive Prostate Cancer — Pedro Barata, MD, MSc
- Study on Combining External and Internal Radiation Therapy for High-Risk Prostate Cancer — University of Virginia
- Study on the Effects of Relugolix vs Leuprolide on Heart Health in Prostate Cancer Patients — Ohio State University Comprehensive Cancer Center
- Access to 68Gallium-PSMA-11 PET Imaging for Prostate Cancer Detection and Treatment Planning — University of California, San Francisco
- Study on Using Targeted Radiation Therapy for Prostate Cancer with Rising PSA Levels After Surgery — Jonsson Comprehensive Cancer Center
- Study on Using Fluciclovine F18 or Ga68-PSMA PET/CT Scans to Improve Prostate Cancer Treatment — Emory University
- Focal Therapy with Stereotactic Body Radiation Therapy (SBRT) for Patients with a Single Prostate Tumor — National Cancer Institute (NCI)
- Study on Golimumab and Apalutamide for Treating Castration-Resistant Prostate Cancer (TRAMP Study) — University of Washington
- Hormone Therapy (Apalutamide) and Image-guided Radiation Therapy for Treating Prostate Cancer: HEATWAVE Trial — Jonsson Comprehensive Cancer Center
- Study on Hypofractionated vs. Conventional Radiation Therapy After Surgery for Prostate Cancer — NRG Oncology
- MRI-Guided Radiation Therapy for Treating High-Risk Prostate Cancer — Thomas Jefferson University
- Study on Atezolizumab-Based Combination Therapy Before Surgery for Men with Localized Prostate Cancer — David Oh
- Study on Urolithin A Supplementation in Men with Prostate Cancer Undergoing Surgery — National Cancer Institute (NCI)
- Study on PSMA or FACBC PET/CT Site-Directed Therapy for Treating Prostate Cancer (Flu-BLAST-PC Study) — University of Washington
- Study on PSMA-Directed Radiation Therapy for Recurrent Prostate Cancer — University of Miami
- Study on Risk-Based Reduced Hormone Therapy with Radiation for Treating Prostate Cancer — Mayo Clinic
- Study on Surgery and Radiation Therapy for Recurrent Prostate Cancer — University of Utah
- Study Comparing Shorter Radiation Therapy to Usual Radiation Therapy for High-Risk Prostate Cancer — NRG Oncology
- Testing the Addition of Niraparib to Usual Hormone and Radiation Therapy for Prostate Cancer with High Recurrence Risk — NRG Oncology
- Study on Adding Apalutamide to Usual Hormone and Radiation Therapy After Prostate Cancer Surgery — NRG Oncology
- Testing the Addition of Relugolix to Radiation Therapy for Advanced Prostate Cancer — NRG Oncology
- Study on Low Dose Apalutamide's Effects on PSA Levels in Men Undergoing Prostate Surgery — National Cancer Institute (NCI)
- Treating Prostate Cancer That Has Returned After Surgery with Apalutamide and Targeted Radiation Based on PET Imaging — ECOG-ACRIN Cancer Research Group
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial — NRG Oncology
- Two Studies for Prostate Cancer Patients: Testing Less Intense Treatment for Low Gene Risk and More Intense Treatment for High Gene Risk — NRG Oncology
- Study on White Button Mushroom Supplement for Reducing PSA Levels in Patients with Recurrent or Untreated Low-Risk Prostate Cancer — City of Hope Medical Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Prostate Adenocarcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.